Application Note: Anti-ETO Antibody has been tested in ChIP and ELISA. Specific conditions for reactivity should be optimized by the end user.
Concentration Value: neat
ELISA Dilution: 1:100
ChIP Dilution: 4 μl/ChIP
General Disclaimer Note: This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
Immunogen: Anti-ETO Antibody was produced in rabbits by repeated immunizations with human ETO using two synthetic peptides containing sequences from the N-terminal and internal region of the protein respectively.
Physical State: Liquid (sterile filtered)
Purity and Specificity: Anti-ETO Antibody is monospecific antiserum processed by delipidation and defibrination followed by sterile filtration. This product reacts with human ETO. Cross reactivity with ETO from other sources is not known.
Background: ETO is a transcriptional regulator which belongs to the myeloid translocation gene family. ETO exerts its function by interaction with transcription factors bound to promoters and binding to histone deacetylases. It recruits a range of corepressors to facilitate transcriptional repression. The t(8;21)(q22;q22) translocation is one of the most frequent karyotypic abnormalities in acute myeloid leukemia. This translocation produces a chimeric gene made up of the 5’-region of AML1 and the 3’-region of the ETO gene. The chimeric protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation. Anti-ETO Antibody is ideal for research in Gene Expression, Transcription and Cancer.
Low Endotoxin: No
English
Deutsch
